Radioligand Therapy Commercialization
Theranostics is moving nuclear medicine beyond diagnostics into targeted therapy, creating new opportunities for hospitals and imaging centers to expand patient access to advanced treatments. However, the supply chain remains a critical hurdle, particularly with short half-life isotopes and decentralized dispensing. As these therapies grow, patient-ready dose preparation and reliable last-mile delivery are essential to keeping workflows efficient and patients on schedule.
Jubilant Radiopharmacies can help bridge the gap between the vial and the patient.
Through our nationwide network of radiopharmacies, we prepare, calibrate, and deliver patient-ready, unit-dose therapeutic prefilled syringes (PFS)—so sites can focus on treating patients, not calibrating radioactive doses.
Product Portfolio / Radioligland Therapies
Your Partner for Radioligand Therapy Commercialization
Radioligand therapies require more than conventional dispensing and last mile delivery. They demand specialized infrastructure, therapeutic-grade radiopharmaceutical regulatory oversight, and coordinated national scale.
Jubilant Radiopharmacies is a leading therapeutic commercialization partner. Our nationwide therapeutic dispensing program—including Lutetium-177-based therapies—is purpose-built to help manufacturers deliver compliant, patient-ready doses at scale. From streamlined site activation to reliable last-mile delivery, we enable efficient, scalable commercial execution across the country.
Support across the therapeutic lifecycle
- Regulatory and radiation safety expertise
- 340B program alignment to expand access and reduce risk
- Proven national infrastructure for scalable, launch-ready operations
- HCP site administration support
Therapeutic products supported in the United States:
- Dispensing partner of Novartis for PLUVICTO®
- SIR-Spheres® Y-90 resin microspheres
Why Jubilant Radiopharmacies?
With experience in radioligand therapy dispensing, including Lutetium-177–based therapies, and a fully integrated national network, Jubilant Radiopharmacies provides the infrastructure required to translate radioligand therapies into scalable clinical practice.
Our bespoke approach extends beyond dispensing and last-mile delivery to include a range of allied services—such as waste management, HCP site enablement and support, 340B program management and financial and contracting support—helping sites operate efficiently while expanding access to advanced therapies.
Patient-Ready Doses
All vials are prepared, calibrated, and delivered as ready-to-administer syringes—eliminating the need for on-site dose calibration or preparation.
National Distribution with Dedicated Fleet
Delivery provided through proprietary transportation fleet of 300+ in-house medical couriers to ensure reliability and time sensitive execution.
Integrated Waste Management
Compliant waste handling and retrieval to support customer site operations.
Radioactive Materials (RAM) Licenses Activated across Entire Network
All Jubilant Radiopharmacies locations are licensed to handle and dispense Lutetium-177-based therapies.
HCP Site Administration Support
Helping HCP sites align site requirements, protocols, workflows, and operations for seamless therapy administration.
Financial and Contracting Support
End-to-end contract management, invoicing, and collection services, including accounts receivable risk mitigation.
340B Program Support
Comprehensive support to expand access and optimize program performance.
Let's Advance the Future of Therapeutics Together
Whether launching, scaling, or expanding a radioligand therapy, Jubilant Radiopharmacies provides the infastructure, expertise, and partnership required for success.
Ready to commercialize your radioligand therapy at scale? Connect with our team via the form below to get started.
Contact Us
To learn more about our portfolio and services, fill out the form to speak with a sales representative.
Contact Us
Reach out to Jubilant Radiopharmacies through our Contact Us form for inquiries, support, and more.